Q1 2025 Bayer AG Earnings Call Transcript
Key Points
- Bayer AG (BAYRY) reported a strong performance in its Pharmaceuticals division with a 4% growth, driven by the exceptional momentum of Nubeqa and Kerendia, which grew 80% year-over-year.
- The company achieved a 12% increase in EBITDA before special items in the Pharmaceuticals division, indicating effective cost management and efficiency gains.
- Consumer Health division saw a 2.5% growth, with a 2% increase in volume, positioning the division well to meet its annual guidance.
- Bayer AG (BAYRY) is on track to meet its full-year guidance for 2025, with core EPS expected to be between EUR4.50 to EUR5.00 at constant currencies.
- The company has made significant progress in its strategic priorities, including the launch of Beyonttra in the EU and preparations for the launch of elinzanetant in the second half of the year.
- Bayer AG (BAYRY) reported a 3% decline in sales for its Crop Science division, primarily due to regulatory impacts affecting higher margin sales.
- The company's free cash flow was negative at EUR1.5 billion, attributed to the seasonality of the Crop business, although it showed improvement from the previous year.
- Xarelto sales declined by 31% due to continued generic pressure in Europe and Japan, impacting the Pharmaceuticals division's top and bottom line.
- The Consumer Health division experienced soft conditions in key markets, with a slight decline in margins compared to the previous year.
- Bayer AG (BAYRY) faces ongoing litigation challenges, including an adverse decision by the Superior Court of Pennsylvania, which may impact financial provisions and require further legal actions.
Good afternoon and good morning everybody and welcome to a conference call to discuss the first quarter results for 2025.
To kick things off, Bill will share his insights on our overall business performance and the progress we've made on our strategic priorities thus far. Wolfgang will then provide further insights into the quarter one financials, the current geopolitical environment, and our outlook for the remainder of the year. The presentations will be followed by our Q&A session, which will also include the presidents of our three divisions.
As a reminder, we invite you also to join us for our Crop Science webinar later today, we start at 4:00 PM Central European Time or 10:00 AM Eastern Time, where we will delve further into the division strategy and outlook.
Before we begin, please note the cautionary language in our Safe Harbor statement.
And with that, over to you, Bill.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
